Pharmaceutical policy regarding generic drugs in Belgium

PharmacoEconomics

Volumn 23, Issue 8, 2005, Pages 755-766

  Simoens, Steven ^a   De Bruyn, Kristien ^b   Bogaert, Marc ^c   Laekeman, Gert ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b Myeloma Study Group   (Belgium)

^c Belgian Centre for Pharmacotherapeutic Information   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CITALOPRAM; CLAVUCID; ESCITALOPRAM; ESOMEPRAZOLE; GENERIC DRUG; LISINOPRIL; LOGASTRIC; NEXIAM; OMEPRAZOLE; PROTON PUMP INHIBITOR; SIMVASTATIN; SIPRALEXA;

BELGIUM; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DRUG COST; DRUG INDUSTRY; DRUG USE; HEALTH CARE POLICY; HEALTH INSURANCE; HUMAN; OUTCOMES RESEARCH; PHARMACIST; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW;

BELGIUM; DRUGS, GENERIC; HEALTH POLICY; LEGISLATION, DRUG;

EID: 26444591589     PISSN: 11707690     EISSN: 11707690     Source Type: Journal    
DOI: 10.2165/00019053-200523080-00002     Document Type: Review

References (19)

1. Griffin JP. An historical survey of UK government measures to control the NHS medicines expenditure from 1948 to 1996. Pharmacoeconomics 1996; 10 (3): 210-24
2. Rijksdienst voor Ziekte-en Invaliditeitsverzekering (State Department for Illness and Invalidity Insurance). Statistics. Brussels: RIZIV, 2003
3. Jacobzone S. Pharmaceutical policies in OECD countries: reconciling social and industrial goals. Labour Market and Social Policy Occasional Papers No. 40. Paris: OECD, 2000
4. Organisation for Economic Co-operation and Development. The OECD Health Project. Towards high-performing health systems. Policy studies. Paris: OECD, 2004
5. Ess SM, Schneeweiss S, Szucs TD. European healthcare policies for controlling drug expenditure. Pharmacoeconomics 2003; 21 (2): 89-103
6. De Joncheere K, Rietveld AH, Huttin C. Experiences with generics. Int J Risk Safety Med 2002; 15: 101-9
7. Garattini L, Tediosi F. A comparative analysis of generics markets in five European countries. Health Policy 2000; 51: 149-62
8. Koninklijk Besluit van 3 juli 1969 betreffende de registratie van geneesmiddelen (Royal Decree of July 3rd, 1969, relating to the registration of drugs). Belgisch Staatsblad 1969 Jul 10
9. Wet betreffende de verplichte verzekering voor geneeskundige verzorging en uitkeringen, gecoördineerd op 14 juli 1994 (GVU wet). (Law concerning the compulsory insurance for health care, co-ordinated on 1994 Jul 14)
10. Wet van 6 augustus 1993 houdende sociale en diverse bepal-ingen (Law of 6th August 1993, concerning social and other stipulations). Belgisch Staatsblad 1993 Aug 9, 17876
11. IMS Health Belgium, Brussels, Belgium. http://www.imshealth.com [Accessed 2004 Nov 8]
12. Instituut voor Farmaco-Epidemiologie van België (Belgian Institute for Pharmaco-Epidemiology), Brussels, Belgium, 2004
13. Mansfield P, Henry D, Tonkin A. Single-enantiomer drugs: elegant science, disappointing effects. Clin Pharmacokinet 2004; 43: 287-90
14. Enantiomeren in plaats van racemische mengsels: een vooruitgang? (Enantiomers instead of racemic compounds: progress?) [online]. Folia Pharmacotherapeutica 2003; 30 (12): 104-5. Available from URL: http://www.bcfi.be [Accessed 2004 Nov 29]
15. Nederlands Huisartsen Genootschap (Dutch Society of General Practitioners). NHG-standaard depressieve stoornis (Dutch Society of General Practitioners' standards for treating depression). Huisarts Wet 2003; 46: 614-23
16. Schwermann T, Greiner W, Schulenburg JM. Using disease management and market reforms to address the adverse economic effects of drug budgets and price and reimbursement regulations in Germany. Value Health 2003; 6: S20-30
17. Gosden T, Torgerson DJ. The effect of fundholding on prescribing and referral costs: a review of the literature. Health Policy 1997; 40: 103-14
18. National Economic Research Associates, YRCR Limited, Ber-win SJ. Policy relating to generic medicines in the OECD. London: National Economic Research Associates, 1999
19. Schwabe U, Paffrath D. Arzneimittelverordnungs: report 2001. Berlin: Springer, 2001